Daily dietary chromium intake in Belgium, using duplicate portion sampling

[Is chromium an essential trace element in human nutrition?]

It has been recognized that chromium is an essential trace element associated with carbohydrate metabolism, and chromium deficiency causes an impaired glucose tolerance. Recently, however, Vincent et al. have reported that chromium is not an essential trace element. In the present report, the author evaluated the nutritional essentiality of chromium by reviewing several previous reports. In almost all previous reports, the chromium concentration in the animal feed used was higher than 0.1 μg/g, and it is difficult to consider that the experimental animals were in a low-chromium state. In addition, the amount of chromium administered to the animals for the improvement of glucose tolerance was at a pharmacological level, and corresponded to a level that far exceeded the human daily chromium intake (20 to 80 μg/day). On the other hand, recent research has clearly shown that feeding with a severely low-chromium diet (0.016 μg/g) does not impair glucose tolerance. The amount of chromium absorbed in humans estimated from chromium intake (20 to 80 μg/day), chromium absorption rate (1%), and urinary chromium excretion (<1 μg/day) is less than 1 μg/day, which is much lower than those of other essential trace elements. In addition, because there is an inconsistency between the chromium concentration in food and chromium intake, chromium intake seems to be dependent on chromium contamination during food processing and cooking. It is concluded that there is a high possibility that chromium is not an essential trace element.

Chromium and iron content in duplicate meals at a university residence: daily intake and dialysability

The objective of the present study was to determine total Cr and Fe content and the corresponding mineral dialysable fraction in a total of sixty-three duplicate meals. Samples of breakfast, lunch and dinner were taken over twenty-one consecutive days at a female university residence in Granada (Spain). Cr content in the duplicate daily meals ranged from 98·50 to 120·80 μg, with a mean of 110·00 μg, and Fe levels ranged from 9·50 to 40·00 mg, with a mean content of 18·50 mg. The mean Cr and Fe dialysable fractions ranged from 0·50 to 1·50 % and from 7·75 to 11·80 %, respectively. Possible correlations with energy and other nutrient intakes were also evaluated. Adherence of the meals to the Mediterranean dietary patterns was tested, and these findings reveal that a balanced and varied diet based on a Mediterranean-style diet plan provides adequate levels and bioaccessibility of Cr and Fe for young women, which is especially important to avoid mineral deficiencies.

Food chromium content, dietary chromium intake and related biological variables in French free-living elderly

Trivalent chromium (Cr3+) is an essential trace element involved in insulin function. Cr deficiencies result in decreased insulin sensitivity, glucose intolerance and an increased risk of diabetes. Cr status decreases with age suggesting that the elderly may be at high risk of Cr deficiency. This study aimed to provide information about the Cr content of foods in France and the Cr intake in French free-living elderly. We measured the food Cr content and daily Cr intake of freely chosen diets for 3 d in twelve French free-living elderly people and their Cr excretion and plasma hormonal related variables, leptin, insulin and cortisol. Considering the relationship between insulin resistance and oxidative stress, we also determined plasma thiobarbituric acid reactive substance, thiol groups and total and reduced glutathione. Although these subjects had well-balanced diets, their daily Cr intakes did not reach the French recommendations. The low Cr intakes were due to the low Cr density of the foods. We found a negative correlation between Cr intakes and insulin, BMI and leptin.

Mineral content in legumes and nuts: contribution to the Spanish dietary intake

We evaluated the levels of essential elements as Cu, Cr, Fe and Zn, and toxic elements as Al, Ni, Pb and Cd in a total of 40 samples of different legumes and 56 samples of different nuts, that are widely consumed in Spain. These elements were determined in the samples mineralized with HNO(3) and V(2)O(5), using electrothermal atomic absorption spectrometry (ETAAS) as the analytical technique. Reliability of the procedure was checked by analysis of a certified reference material. No matrix effects were observed and aqueous standard solutions were used for calibration. In legumes, the levels ranged from 1.5-5.0 microg Cu/g, 0.05-0.60 microg Cr/g, 18.8-82.4 microg Fe/g, 32.6-70.2 microg Zn/g, 2.7-45.8 microg Al/g, 0.02-0.35 microg Ni/g, 0.32-0.70 microg Pb/g and not detectable-0.018 microg Cd/g. In nuts, the levels ranged from 4.0-25.6 microg Cu/g, 0.25-1.05 microg Cr/g, 7.3-75.6 microg Fe/g, 25.6-69.0 microg Zn/g, 1.2-20.1 microg Al/g, 0.10-0.64 microg Ni/g, 0.14-0.39 microg Pb/g, and not detectable-0.018 microg Cd/g. A direct statistical correlation between Cu-Cr, Zn-Al and Cr-Ni (P<0.05), and Al-Pb (P<0.001), has been found. The growing popularity of these products in recent years on the basis of its nutritional properties and beneficial effects, requires additional data and a periodical control. In addition, the present findings are of potential use to food composition tables.

Daily dietary intake of chromium in southern Spain measured with duplicate diet sampling

We measured daily dietary Cr intake in southern Spain by sampling duplicate diets for seven consecutive days in different population groups. Cr was determined by electrothermal atomization-atomic absorption spectrometry. The samples were mineralized in a digestion block with HNO(3), HClO(4) and V(2)O(5). A total of 161 duplicate diets from twenty-three subjects were analysed, and mean levels of Cr intake ranged from 9.39 to 205.16 microg/d. Mean Cr intake (100 microg/d) was similar to levels found for most other countries, and was within the range recommended by the National Research Council for a safe and adequate daily intake (50-200 microg/d). Chromium intake correlated significantly with energy, protein and carbohydrate intake, and with the daily intake of Zn, Fe, Mg, K, Na, Ca and nicotinic acid in the diets analysed.

Estimation of chromium bioavailability from the diet by an in vitro method

An in vitro method was used to study the dialysable fraction of chromium (Cr) from the diet which simulates human gastric and intestinal digestion. The percentage of dialysed Cr was used to assess the bioavailability. The duplicate diet approach was used to obtain ten different sets of samples each representative of the normal diet consumed in southern Spain. In each case triplicate analysis of Cr was carried out by electrothermal atomization-atomic absorption spectrometry in acid-mineralized samples. The Cr dietary intake ranged from 16 to 117 microg/day, and the dialysable Cr fraction ranged from 0.4% to 1.6%. The Cr absorption was higher for low levels of daily dietary intake of Cr (< 40 microg) than for levels of 40-80 microg; for high levels (> 80 microg) there was an increase in the dialysable fraction. The energy and nutrient intake of these diets was also evaluated.

Reversal of corticosteroid-induced diabetes mellitus with supplemental chromium

AIMS

To determine if the stress of corticosteroid treatment increases chromium (Cr) losses and if corticosteroid-induced diabetes (steroid diabetes) can be reversed by supplemental chromium.

METHODS

The effects of corticosteroid treatment on chromium losses of 13 patients 2 days prior to steroid administration and the first 3 days following treatment were determined. Since steroid-induced diabetes was associated with increased chromium losses and insufficient dietary chromium is associated with glucose intolerance and diabetes, we treated three patients with steroid-induced diabetes with 600 microg per day of chromium as chromium picolinate.

RESULTS

Urinary chromium losses following corticosteroid treatment increased from 155+/-28 ng/d before corticosteroid treatment to 244+/-33 ng/d in the first 3 days following treatment. Chromium supplementation of patients with steroid-induced diabetes resulted in decreases in fasting blood glucose values from greater than 13.9 mmol/l (250 mg/dl) to less than 8.3 mmol/l (150 mg/dl). Hypoglycaemic drugs were also reduced 50% in all patients when given supplemental chromium.

CONCLUSIONS

These data demonstrate that corticosteroid treatment increases chromium losses and that steroid-induced diabetes can be reversed by chromium supplementation. Follow-up, double-blind studies are needed to confirm these observations.

Chromium, glucose intolerance and diabetes

Within the last 5 years chromium (Cr) has been shown to play a role in glucose intolerance, Type 2 diabetes mellitus (Type 2 DM), and gestational diabetes. In addition, diabetes and the neuropathy of a patient on home parenteral nutrition were alleviated when supplemental Cr was added to total parenteral nutrition (TPN) solutions. In a study conducted in China that has been supported by studies in the United States, supplemental Cr as Cr picolinate improved the blood glucose, insulin, cholesterol, and hemoglobin A1C in people with Type 2 DM in a dose dependent manner. Follow-up studies of > 1 year have confirmed these studies. The requirement for Cr is related to the degree of glucose intolerance: 200 microg/day of supplemental Cr is adequate to improve glucose variables of those who are mildly glucose intolerant. However, people with more overt impairments in glucose tolerance and diabetes usually require more than 200 microg/day. Daily intake of 8 microg of Cr per kg body weight was also more effective than 4 microg/kg in women with gestational diabetes. The mechanism of action of Cr involves increased insulin binding, increased insulin receptor number, and increased insulin receptor phosphorylation. In summary, supplemental Cr has been shown to have beneficial effects without any documented side effects on people with varying degrees of glucose intolerance ranging from mild glucose intolerance to overt Type 2 DM.